Treatment of Chronic Mycobacterium Avium-Intracellulare (MAI) Pulmonary Infection

Initial Diagnostic Confirmation

The American Thoracic Society recommends obtaining three separate sputum samples or bronchoscopic specimens for acid-fast bacilli culture to establish true infection versus colonization, and using high-resolution CT (HRCT) chest as the preferred imaging modality 2
Exclude other underlying conditions that predispose to MAI, including cystic fibrosis, immunodeficiency states, HIV infection, primary ciliary dyskinesia, and allergic bronchopulmonary aspergillosis 2

The American College of Chest Physicians recommends initiating combination antimycobacterial therapy with a macrolide (clarithromycin 500 mg orally twice daily OR azithromycin 500 mg daily) plus ethambutol 15 mg/kg orally once daily, with or without rifampin 450-600 mg once daily (or rifabutin 300 mg once daily), and continuing treatment for 12 months after sputum culture conversion 1
Clarithromycin 500 mg orally twice daily is the preferred macrolide, and the dose should not be increased to 1,000 mg twice daily due to increased mortality risk 3 4
Ethambutol 15 mg/kg orally once daily and rifampin 450-600 mg orally once daily OR rifabutin 300 mg orally once daily are also recommended 3 4 5

For HIV-positive patients with disseminated MAI, lifelong suppressive therapy is required after initial treatment of disseminated disease, using the same macrolide-ethambutol combination with or without rifabutin 3 4
The Infectious Diseases Society of America recommends that maintenance therapy should not be discontinued even if CD4+ counts improve to >100 cells/mm³ with HAART 3 4
For pregnant women, azithromycin plus ethambutol are the preferred agents, and rifamycins should be avoided when possible due to potential teratogenicity 3 4

The American College of Radiology recommends monthly sputum cultures until conversion, then every 3 months, and chest CT at 6-12 month intervals to assess radiographic response and disease progression 6
Monitor for drug toxicity, including hepatotoxicity (rifamycins), optic neuritis (ethambutol), and QT prolongation (macrolides) 5
Assess for treatment failure if no clinical improvement after 3-6 months or persistent positive cultures after 6 months 5

For localized disease with intolerable symptoms despite maximal medical therapy, surgical resection may be offered for focal bronchiectasis or solitary nodules causing hemoptysis or recurrent infections 2

Do not treat colonization: ensure diagnostic criteria are met before initiating therapy, as MAI isolation alone does not mandate treatment 2
Do not use monotherapy: always use combination therapy to prevent resistance 5
Do not stop therapy prematurely: treatment must continue for 12 months after culture conversion, not just symptom resolution 1